Infiltrating Bladder Urothelial Carcinoma Clinical Trial
Official title:
Prospective Study of Bladder-Preservation Chemo-Radiotherapy (Partial Bladder Hypo-fractionated Radiotherapy) for Patients With Muscle-Invasive Bladder Cancer
This research trial studies quality of life after bladder-preservation chemotherapy and radiation therapy (chemo-radiotherapy) in patients with bladder cancer that has spread into or through the muscle layer of the bladder (muscle-invasive bladder cancer). Bladder-preservation chemo-radiotherapy is a standard treatment for patients with muscle-invasive bladder cancer, however, chemo-radiotherapy may cause urinary tract, bowel, and sexual late side effects that negatively affect patients' quality of life. Studying quality-of-life in patients with muscle-invasive bladder cancer after chemo-radiotherapy may help identify the long-term side effects of treatment and may help plan the best treatment in the future and improve patients' quality of life.
PRIMARY OBJECTIVES:
I. To study health-related quality of life (HRQoL, or QOL) for patients undergoing
protocol-based bladder-preservation chemo-radiation.
OUTLINE:
Patients complete the European Organization for Research and Treatment for Cancer (EORTC)
QLQ-Bladder Cancer Muscle Invasive (BLM-C30) at baseline, every 3 months for 1 year, every 4
months for 1 year, every 6 months for 3 years, and then annually thereafter after completion
of chemo-radiotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02944357 -
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
|
N/A | |
| Active, not recruiting |
NCT01616875 -
Bristol Bladder Trial
|
Phase 2 | |
| Active, not recruiting |
NCT01495676 -
A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer
|
N/A | |
| Withdrawn |
NCT03419130 -
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
|
Phase 2 | |
| Withdrawn |
NCT03238664 -
Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors
|
N/A | |
| Active, not recruiting |
NCT03549715 -
NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT02767921 -
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
|
Phase 1 | |
| Recruiting |
NCT03609216 -
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
|
Phase 2 |